NovoCure Ltd(NVCR)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
NovoCure Ltd (NVCR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVCR at 37.5/100 on a 32-signal composite quality model, placing it at rank #2,231 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NovoCure Ltd reports quarterly revenue of $183.6M, net income of $-15.7M, free cash flow of $1.2M. Top institutional holders of NVCR by reported 13-F value include FMR, BlackRock, Soleus Capital Management, L.P., based on the most recent SEC filings. NVCR trades on the Nasdaq exchange and files with the SEC under CIK 1645113. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NovoCure Ltd directly from SEC EDGAR.
AI Quality Score
37.5/100
AI Rank
#2,231
Revenue
$183.6M
Net Income
$-15.7M
Free Cash Flow
$1.2M
NVCR key financials by period
NovoCure Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$655.4M
$-136.2M
-23.5%
FY 2024
10-K
$605.2M
$-168.6M
-28.2%
FY 2023
10-K
$509.3M
$-207.0M
-45.7%
FY 2022
10-K
$537.8M
$-92.5M
-16.6%
FY 2021
10-K
$535.0M
$-58.4M
-8.3%
FY 2020
10-K
$494.4M
$19.8M
6.2%
Institutions holding NVCR
Institutional investors reporting a position in NovoCure Ltd on SEC Form 13F.
